Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Raising the profile of cancer of unknown primary.

Oien KA, Evans TR.

J Clin Oncol. 2008 Sep 20;26(27):4373-5. doi: 10.1200/JCO.2008.17.6156. No abstract available.

PMID:
18802148
2.

Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD.

J Clin Oncol. 2008 Sep 20;26(27):4442-8. doi: 10.1200/JCO.2007.14.4378.

PMID:
18802157
3.

The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?

Prasad V, Oseran A, Fakhrejahani F.

Eur J Cancer. 2016 Feb;54:159-62. doi: 10.1016/j.ejca.2015.09.006. Epub 2015 Nov 19. No abstract available.

PMID:
26608119
4.

Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.

Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN.

Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599. Epub 2011 Apr 29.

5.

New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.

Varadhachary G.

Clin Cancer Res. 2013 Aug 1;19(15):4027-33. doi: 10.1158/1078-0432.CCR-12-3030. Epub 2013 Mar 21.

6.

Diagnostic evaluation of patients with carcinoma of unknown primary tumor site.

Leonard RJ, Nystrom JS.

Semin Oncol. 1993 Jun;20(3):244-50. Review. No abstract available.

PMID:
8503020
7.

[Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].

Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G.

Pathologe. 2009 Dec;30 Suppl 2:168-72. doi: 10.1007/s00292-009-1194-4. German.

PMID:
19756615
8.

Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary.

Nguyen TT, Kreisel FH, Frater JL, Bartlett NL.

J Clin Oncol. 2013 Nov 20;31(33):e443-5. doi: 10.1200/JCO.2012.46.7910. Epub 2013 Jun 17. No abstract available.

PMID:
23775969
9.

[Primary branchiogenic carcinoma or metastasis of an unknown epidermoid cancer].

García Díaz J, Barrios JM, Viel JM, Huwaidi M.

An Otorrinolaringol Ibero Am. 1991;18(5):491-7. Review. Spanish. No abstract available.

PMID:
1781517
10.

Management of peritoneal carcinomatosis of unknown primary tumor site.

Muggia FM, Baranda J.

Semin Oncol. 1993 Jun;20(3):268-72. Review. No abstract available.

PMID:
8503022
11.

Carcinoma of unknown primary: searching for the origin of metastases.

Carlson HR.

JAAPA. 2009 Aug;22(8):18-21. Review. No abstract available.

PMID:
19725409
12.

Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI.

Gross-Goupil M, Massard C, Lesimple T, Merrouche Y, Blot E, Loriot Y, Mathieu MC, Fizazi K.

Onkologie. 2012;35(1-2):54-5. doi: 10.1159/000336300. Epub 2012 Jan 23. No abstract available.

13.

A primary approach to cancers of unknown primary.

Schwartz AM, Harpaz N.

J Natl Cancer Inst. 2013 Jun 5;105(11):759-61. doi: 10.1093/jnci/djt115. Epub 2013 May 2. No abstract available.

PMID:
23641044
14.

Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary.

Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Goussia A, Stoyianni A, Sanden M, St Cyr B, Yerushalmi N, Benjamin H, Meiri E, Chajut A, Rosenwald S, Aharonov R, Spector Y.

Mol Cancer. 2013 Jun 10;12:57. doi: 10.1186/1476-4598-12-57.

15.

Microarray analysis as a helpful tool in identifying the primary tumour in cancer with an unknown primary site.

Soesan M, de Snoo F, Westerga J, Floore A, Bender R.

Neth J Med. 2010 Jan;68(1):50-1. No abstract available.

16.

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D.

J Clin Oncol. 2008 Sep 20;26(27):4435-41. doi: 10.1200/JCO.2007.14.6969.

PMID:
18802156
17.

[Peritoneal carcinomatosis of unknown origin].

Marchal N, Gennigens C, Jerusalem G.

Rev Med Liege. 2012 Nov;67(11):582-6. Review. French.

PMID:
23346828
18.

Poorly differentiated neuroendocrine carcinoma of unknown primary tumor site.

Garrow GC, Greco FA, Hainsworth JD.

Semin Oncol. 1993 Jun;20(3):287-91. Review. No abstract available.

PMID:
8503025
19.

Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.

Tan DS, Montoya J, Ng QS, Chan KS, Lynette O, Sakktee Krisna S, Takano A, Lim WT, Tan EH, Lim KH.

J Clin Oncol. 2013 May 10;31(14):e237-9. doi: 10.1200/JCO.2012.44.3937. Epub 2013 Apr 1. No abstract available.

PMID:
23547070
20.

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Hainsworth JD, Greco FA.

Virchows Arch. 2014 Apr;464(4):393-402. doi: 10.1007/s00428-014-1545-2. Epub 2014 Feb 1. Review.

PMID:
24487792

Supplemental Content

Support Center